elzovantinib   Click here for help

GtoPdb Ligand ID: 11869

Synonyms: compound 5 [WO2019023417A1] | CSF1R-IN-2 | TPX-0022 | TPX002
Compound class: Synthetic organic
Comment: Elzovantinib (TPX-0022) is a MET tyrosine kinase inhibitor that targets the SRC and CSF1R pathways in cancers [1]. It has demonstrated activity in patients with MET-driven gastric cancer in Phase 1 clinical trial.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 121.57
Molecular weight 409.17
XLogP 2.89
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCN1Cc2c(ccc(c2C#N)F)O[C@@H](C)CNC(=O)c2c3nc1ccn3nc2N
Isomeric SMILES CCN1Cc2c(ccc(c2C#N)F)O[C@H](CNC(=O)c2c3nc1ccn3nc2N)C
InChI InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1
InChI Key UUDPUQDMSHQSKH-NSHDSACASA-N
No information available.
Summary of Clinical Use Click here for help
Turning Point Therapeutics have advanced TPX-0022 into clinical evaluation. TPX-0022 was granted orphan drug designation by the FDA (in June 2021) as a treatment for patients with gastric cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03993873 Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Phase 1 Interventional Turning Point Therapeutics, Inc.